Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects
treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone
following hematopoietic cell transplantation (HCT). The purpose of this study is to test the
hypothesis that subjects receiving pamidronate with calcium and vitamin D will have higher
lumbar spine bone mineral content (LBMC) measured by dual-energy X-ray tomography (DXA) at 1
year post-HCT than subjects receiving calcium and vitamin D alone (Control Group).
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Calcium Calcium, Dietary Cholecalciferol Ergocalciferols Pamidronate Vitamin D Vitamins